Forxiga was approved for CKD on the strength of the DAPA-CKD trial, which found that adding the drug to standard care in people with CKD reduced the risk of worsening renal function, the onset of ...

Updates on chronic kidney disease (CKD) diagnosis, use of sodium–glucose cotransporter-2 (SGLT-2) inhibitors as first-line therapy, and personalized treatment approaches for kidney and ...

This leaflet answers some common questions about DAPA-TABS. It is not to be used in relation to any other product, which may also contain the same active ingredient. It does not contain all of the ...